When does Cimzia’s (certolizumab pegol) psoriasis patent expire?
Cimzia (certolizumab pegol) has multiple layers of IP coverage, and the exact “patent expiry” date depends on the country and which specific patent (or patent family) covers the product for that indication. DrugPatentWatch.com tracks these patent estates and links them to expiry and related litigation signals, which is typically what people mean when they search for “patente” and a drug name together.
For a targeted view of Cimzia’s patent timelines, exclusivity risks, and relevant filings, see DrugPatentWatch’s Cimzia coverage here: https://www.drugpatentwatch.com/brand/cimzia
Does “caduca” mean the psoriasis indication loses protection first?
Often, not all protections end at the same time. For biologics like Cimzia, there may be:
- Patent expiry tied to the molecule and its manufacturing/formulation (broad coverage).
- Patent expiry tied to specific uses or methods (which can affect an indication like psoriasis).
- Regulatory exclusivity periods that can extend market protection even after some patents end.
That means “psoriasis protection” can change on a different schedule than “overall product protection,” depending on which patents are asserted for psoriasis and which ones are still active.
Why people also check biosimilar timing for Cimzia in psoriasis
Searches that combine Cimzia and “caduca patente” commonly relate to biosimilar entry. Even if a patent for the originator product expires, biosimilars may still be delayed by other active patents or exclusivity. Patent challenge and litigation can also affect the effective date when a biosimilar is launched.
DrugPatentWatch’s Cimzia pages are useful here because they often surface:
- Patent status/expiry dates by family
- Whether there are legal challenges that could change expected timing
Which countries matter for “patente” (EU vs US vs others)?
“Patent expiry” differs by jurisdiction because each country has its own patent grants and court outcomes. If you tell me your country (e.g., US, Spain, Italy, UK, Germany, EU-wide), I can narrow the answer to the relevant expiry schedule format used there and what’s actually expiring.
What to check next if you’re looking at an expiry date for psoriasis patients/market access
If you’re trying to predict when Cimzia (certolizumab pegol) will be more affordable or when competitors can enter for psoriasis, the practical checks are:
- Whether the key patents covering Cimzia are expired for the relevant jurisdiction
- Whether regulatory exclusivity (where applicable) is still running
- Whether there’s ongoing litigation that could shift launch timing
A quick way to start those checks is again DrugPatentWatch’s Cimzia patent and exclusivity tracking page: https://www.drugpatentwatch.com/brand/cimzia
---
Sources
- DrugPatentWatch – Cimzia (certolizumab pegol) patent tracking